The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

@article{Schaik2011TheCG,
  title={The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.},
  author={Ron H. N. van Schaik and M. E. de Kok and Fred C G J Sweep and Martin van Vliet and Marianne van Fessem and Marion E. Meijer-van Gelder and Caroline S Seynaeve and Jan W. Lindemans and Jelle Wesseling and Laura J van 't Veer and Paul N Span and Hanneke W. M. van Laarhoven and Stefan Sleijfer and John A. Foekens and Sabine Linn and Els M. J. J. Berns},
  journal={Pharmacogenomics},
  year={2011},
  volume={12 8},
  pages={1137-46}
}
AIMS Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients. MATERIALS & METHODS A total of 499 estrogen receptor-positive primary breast tumor specimens of advanced disease patients treated with first-line tamoxifen were genotyped for CYP2C19*2 and *17 variant alleles… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…